Trial Profile
A randomized, double-blind comparison of atomoxetine hydrochloride augmented with either extended-release methylphenidate hydrochloride (Concerta) or placebo in children with attention-deficit/hyperactivity disorder (ADHD) who have not responded to stimulant mono therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jun 2007
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary) ; Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 20 Jun 2007 New trial record.